New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression.
暂无分享,去创建一个
[1] J. Quigley,et al. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. , 2010, Biochimica et biophysica acta.
[2] L. Matrisian,et al. The other side of MMPs: Protective roles in tumor progression , 2007, Cancer and Metastasis Reviews.
[3] C. Muller,et al. The membrane form of the DNA repair protein Ku interacts at the cell surface with metalloproteinase 9 , 2004, The EMBO journal.
[4] M. Muche,et al. The alpha 2 chain of collagen type VI sequesters latent proforms of matrix-metalloproteinases and modulates their activation and activity. , 2009, Matrix biology : journal of the International Society for Matrix Biology.
[5] C. Overall,et al. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. , 2010, Biochimica et biophysica acta.
[6] Ø. Bruserud,et al. The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia. , 2010, Current medicinal chemistry.
[7] Z. Han,et al. Matrix metalloproteinases in bone marrow: roles of gelatinases in physiological hematopoiesis and hematopoietic malignancies. , 2006, Histology and histopathology.
[8] M. Moses,et al. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Weiss,et al. Secreted Versus Membrane-anchored Collagenases , 2009, The Journal of Biological Chemistry.
[10] P. Poyet,et al. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. , 2001, Seminars in oncology.
[11] C. Demur,et al. Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features , 2008, Cell cycle.
[12] M. Gujrati,et al. MMP-9 short interfering RNA induced senescence resulting in inhibition of medulloblastoma growth via p16(INK4a) and mitogen-activated protein kinase pathway. , 2007, Cancer research.
[13] E. Koivunen,et al. Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression. , 2006, Blood.
[14] C. Overall,et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. , 2000, Science.
[15] R. Hynes,et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. , 2003, Cancer cell.
[16] T. Turpeenniemi‐Hujanen,et al. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. , 2005, Biochimie.
[17] P. Bornstein,et al. The Low Density Lipoprotein Receptor-related Protein Modulates Levels of Matrix Metalloproteinase 9 (MMP-9) by Mediating Its Cellular Catabolism* , 2001, The Journal of Biological Chemistry.
[18] K. Conant,et al. Matrix Metalloproteinase 1 Interacts with Neuronal Integrins and Stimulates Dephosphorylation of Akt* , 2004, Journal of Biological Chemistry.
[19] K. Brew,et al. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. , 2010, Biochimica et biophysica acta.
[20] A. Paller,et al. Ganglioside GM3 Inhibits Matrix Metalloproteinase-9 Activation and Disrupts Its Association with Integrin* , 2003, Journal of Biological Chemistry.
[21] L. Coussens,et al. Matrix metalloproteinase-2 and -9 expression increases in Mycoplasma-infected airways but is not required for microvascular remodeling. , 2004, American journal of physiology. Lung cellular and molecular physiology.
[22] S. Rafii,et al. Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand , 2002, Cell.
[23] P. Allavena,et al. Cancer-related inflammation , 2008, Nature.
[24] D. Sullivan,et al. A Phase I Pharmacokinetic and Pharmacodynamic Study of S-3304, a Novel Matrix Metalloproteinase Inhibitor, in Patients with Advanced and Refractory Solid Tumors , 2007, Clinical Cancer Research.
[25] C. Gahmberg,et al. Intracellular and Cell Surface Localization of a Complex between αMβ2 Integrin and Promatrix Metalloproteinase-9 Progelatinase in Neutrophils1 , 2004, The Journal of Immunology.
[26] L. Holubec,et al. Biological activity and clinical implications of the matrix metalloproteinases. , 2008, Anticancer research.
[27] Y Ikawa,et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[28] C. Overall,et al. Dissecting the Role of Matrix Metalloproteinases (MMP) and Integrin αvβ3 in Angiogenesis In vitro: Absence of Hemopexin C Domain Bioactivity, but Membrane-Type 1-MMP and αvβ3 Are Critical , 2005 .
[29] Shigeyoshi Itohara,et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.
[30] B. Cauwe,et al. The Biochemical, Biological, and Pathological Kaleidoscope of Cell Surface Substrates Processed by Matrix Metalloproteinases , 2007, Critical reviews in biochemistry and molecular biology.
[31] B. Bauvois,et al. Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons , 2002, Leukemia.
[32] Masanori Hangai,et al. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. , 2002, The American journal of pathology.
[33] J. S. Rao,et al. MMP‐2 alters VEGF expression via αVβ3 integrin‐mediated PI3K/AKT signaling in A549 lung cancer cells , 2009, International journal of cancer.
[34] C. López-Otín,et al. Emerging roles of proteases in tumour suppression , 2007, Nature Reviews Cancer.
[35] D. Cheresh,et al. Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity , 1998, Cell.
[36] W. Stetler-Stevenson,et al. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. , 2010, Seminars in cancer biology.
[37] J. Becker,et al. Role of matrix metalloproteinases in melanoma cell invasion. , 2005, Biochimie.
[38] M. Björklund,et al. Identification of a Negatively Charged Peptide Motif within the Catalytic Domain of Progelatinases That Mediates Binding to Leukocyte β2 Integrins* , 2003, Journal of Biological Chemistry.
[39] C. Lynch. Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis. , 2011, Bone.
[40] B. Sheu,et al. A novel role of metalloproteinase in cancer-mediated immunosuppression. , 2001, Cancer research.
[41] P. Harari,et al. Understanding resistance to EGFR inhibitors—impact on future treatment strategies , 2010, Nature Reviews Clinical Oncology.
[42] M. Terol,et al. Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. , 2008, Blood.
[43] P. Ferdinandy,et al. Matrix Metalloproteinase Inhibitors , 2010, Drugs.
[44] Christopher M. Overall,et al. Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.
[45] G. Giannelli,et al. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. , 1997, Science.
[46] A. Dufour,et al. Role of Matrix Metalloproteinase-9 Dimers in Cell Migration , 2010, The Journal of Biological Chemistry.
[47] S. Meroueh,et al. Cell surface association of matrix metalloproteinase-9 (gelatinase B) , 2003, Cancer and Metastasis Reviews.
[48] Z. Werb,et al. Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.
[49] R. Fridman,et al. Density‐dependent regulation of cell‐surface association of matrix metalloproteinase‐2 (MMP‐2) in breast‐carcinoma cells , 1998, International journal of cancer.
[50] B. Fingleton,et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.
[51] A. Dufour,et al. Role of the hemopexin domain of matrix metalloproteinases in cell migration , 2008, Journal of cellular physiology.
[52] R. Dwek,et al. The Hemopexin and O-Glycosylated Domains Tune Gelatinase B/MMP-9 Bioavailability via Inhibition and Binding to Cargo Receptors* , 2006, Journal of Biological Chemistry.
[53] R. Cardiff,et al. CD44v3,8–10 is involved in cytoskeleton‐mediated tumor cell migration and matrix metalloproteinase (MMP‐9) association in metastatic breast cancer cells , 1998 .
[54] B. Marmer,et al. Substrate Binding of Gelatinase B Induces Its Enzymatic Activity in the Presence of Intact Propeptide* , 2002, The Journal of Biological Chemistry.
[55] P. E. Van den Steen,et al. Neutrophil MMP-9 Proenzyme, Unencumbered by TIMP-1, Undergoes Efficient Activation in Vivo and Catalytically Induces Angiogenesis via a Basic Fibroblast Growth Factor (FGF-2)/FGFR-2 Pathway* , 2009, The Journal of Biological Chemistry.
[56] J. Becker,et al. Coexpression of Integrin αvβ3 and Matrix Metalloproteinase-2 (MMP-2) Coincides with MMP-2 Activation: Correlation with Melanoma Progression , 2000 .
[57] S. Vandenberg,et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. , 2008, Cancer cell.
[58] R. Sedláček,et al. Matrix Metalloproteinase-19 Is Expressed in Myeloid Cells in an Adhesion-Dependent Manner and Associates with the Cell Surface1 , 2002, The Journal of Immunology.
[59] Jingsong Xu,et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo , 2001, The Journal of cell biology.
[60] Carlos López-Otín,et al. Strategies for MMP inhibition in cancer: innovations for the post-trial era , 2002, Nature Reviews Cancer.
[61] W. Schiemann,et al. Transforming growth factor-β and the hallmarks of cancer. , 2011, Cellular signalling.
[62] Z. Werb,et al. New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.
[63] C. Gahmberg,et al. Intracellular and cell surface localization of a complex between alphaMbeta2 integrin and promatrix metalloproteinase-9 progelatinase in neutrophils. , 2004, Journal of immunology.
[64] J. Becker,et al. Coexpression of integrin alpha(v)beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. , 2000, The Journal of investigative dermatology.
[65] A. Gaultier,et al. The Hemopexin Domain of Matrix Metalloproteinase-9 Activates Cell Signaling and Promotes Migration of Schwann Cells by Binding to Low-Density Lipoprotein Receptor-Related Protein , 2008, The Journal of Neuroscience.
[66] S. Weiss,et al. A cancer cell metalloprotease triad regulates the basement membrane transmigration program. , 2006, Genes & development.
[67] R. Fleischmajer,et al. Tetracyclines: nonantibiotic properties and their clinical implications. , 2006, Journal of the American Academy of Dermatology.
[68] J. Woodgett,et al. IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. , 2006, Immunity.
[69] Lisa S. Chen,et al. Inflammation and survival pathways: chronic lymphocytic leukemia as a model system. , 2010, Biochemical pharmacology.
[70] A. Saven,et al. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[71] M. Eck,et al. The FERM domain: organizing the structure and function of FAK , 2010, Nature Reviews Molecular Cell Biology.
[72] R. Bischoff,et al. Physiology and pathophysiology of matrix metalloproteases , 2010, Amino Acids.
[73] P. E. Van den Steen,et al. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. , 2000, Blood.
[74] T. Salo,et al. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. , 2005, Experimental cell research.
[75] W. Kamps,et al. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. , 2004, Critical reviews in oncology/hematology.
[76] David B. Alexander,et al. The Membrane-Anchored MMP Inhibitor RECK Is a Key Regulator of Extracellular Matrix Integrity and Angiogenesis , 2001, Cell.
[77] A. Czirók,et al. Matrix metalloproteinase 2-integrin alpha(v)beta3 binding is required for mesenchymal cell invasive activity but not epithelial locomotion: a computational time-lapse study. , 2008, Molecular biology of the cell.
[78] H. Nagase,et al. MMPs Are IGFBP‐Degrading Proteinases: Implications for Cell Proliferation and Tissue Growth , 1999, Annals of the New York Academy of Sciences.
[79] X. Wang,et al. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma , 2007, Oncogene.
[80] W. Stetler-Stevenson,et al. Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin αvβ3 , 1996, Cell.
[81] R. Fridman,et al. Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells. , 1997, Cancer research.
[82] P. Sharma,et al. Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors: a review. , 2011, Current medicinal chemistry.
[83] Y. Ma,et al. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[84] C. Overall,et al. Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)beta3 in angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and alpha(v)beta3 are critical. , 2005, Cancer research.
[85] L. Devy,et al. New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies , 2010, Biochemistry research international.
[86] T. Stricker,et al. Pro-collagenase-1 (Matrix Metalloproteinase-1) Binds the α2β1 Integrin upon Release from Keratinocytes Migrating on Type I Collagen* , 2001, The Journal of Biological Chemistry.
[87] J. Hohneker,et al. Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors. , 2003, Seminars in oncology.
[88] D. Scadden,et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] I. Stamenkovic,et al. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. , 1999, Genes & development.
[90] D. Boger,et al. Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[91] D. Ruiter,et al. Expression of integrin αvβ3 correlates with activation of membrane‐type matrix metalloproteinase‐1 (MT1‐MMP) and matrix metalloproteinase‐2 (MMP‐2) in human melanoma cells in vitro and in vivo , 2000 .
[92] I. Sagi,et al. Structural and functional bases for allosteric control of MMP activities: can it pave the path for selective inhibition? , 2010, Biochimica et biophysica acta.
[93] R. Hynes,et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. , 2003, Cancer cell.
[94] Jin-Ao Duan,et al. Selective matrix metalloproteinase inhibitors for cancer. , 2009, Current medicinal chemistry.
[95] C. Gialeli,et al. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting , 2011, The FEBS journal.
[96] P. E. Van den Steen,et al. Gelatinase B/matrix metalloproteinase‐9 cleaves interferon‐β and is a target for immunotherapy , 2003 .
[97] I. Stamenkovic,et al. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.
[98] Pedro Romero,et al. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity , 2002, Oncogene.
[99] A. Karsan,et al. Activation of metalloproteinases and their association with integrins: an auxiliary apoptotic pathway in human endothelial cells , 2002, Cell Death and Differentiation.
[100] P. E. Van den Steen,et al. Beta-hematin interaction with the hemopexin domain of gelatinase B/MMP-9 provokes autocatalytic processing of the propeptide, thereby priming activation by MMP-3. , 2008, Biochemistry.
[101] Christopher M Overall,et al. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. , 2006, Nature reviews. Cancer.
[102] P. Bornstein,et al. Extracellular Matrix Metalloproteinase 2 Levels Are Regulated by the Low Density Lipoprotein-related Scavenger Receptor and Thrombospondin 2* , 2001, The Journal of Biological Chemistry.
[103] H. Nagase,et al. Progress in matrix metalloproteinase research. , 2008, Molecular aspects of medicine.
[104] M. Terol,et al. Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain. , 2010, Cancer cell.
[105] J. S. Rao,et al. Blockade of Tumor Growth Due to Matrix Metalloproteinase-9 Inhibition Is Mediated by Sequential Activation of β1-Integrin, ERK, and NF-κB* , 2008, Journal of Biological Chemistry.
[106] A. Saven,et al. Activated integrin αvβ3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[107] J. Sparano,et al. Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi’s sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial , 2011, Cancer Chemotherapy and Pharmacology.
[108] S. Rafii,et al. A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization. , 2008, Cancer cell.
[109] M. Björklund,et al. Gelatinase-mediated migration and invasion of cancer cells. , 2005, Biochimica et biophysica acta.
[110] Y. Yano,et al. Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers. , 2007, British journal of clinical pharmacology.
[111] W. Stetler-Stevenson,et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. , 1996, Cell.
[112] C. Overall,et al. Towards third generation matrix metalloproteinase inhibitors for cancer therapy , 2006, British Journal of Cancer.
[113] Y. Okada,et al. Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases , 2003, Oncogene.
[114] R. Khokha,et al. The Role of Tissue Inhibitors of Metalloproteinases in Tumorigenesis and Metastasis , 2008, Critical reviews in clinical laboratory sciences.
[115] M. Björklund,et al. Peptide Inhibition of Catalytic and Noncatalytic Activities of Matrix Metalloproteinase-9 Blocks Tumor Cell Migration and Invasion* , 2004, Journal of Biological Chemistry.